Vaccins against malaria: A new perspective;Vaccins tegen malaria: Nieuw perspectief

Nederlands Tijdschrift voor Geneeskunde

Volumn 144, Issue 2, 2000, Pages 64-69

  Sauerwein, R W ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MALARIA VACCINE; PROTOZOAL PROTEIN;

ARTICLE; IMMUNE RESPONSE; LIFE CYCLE; MALARIA; PLASMODIUM FALCIPARUM; VACCINATION; ANIMAL; HEALTH; HUMAN; IMMUNOLOGY; MALARIA FALCIPARUM; REVIEW;

ANIMALS; HUMANS; MALARIA VACCINES; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; WORLD HEALTH;

EID: 0034620263     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. World Health Organization. Severe and complicated malaria. 2nd ed. Trans Roy Soc Trop Med Hyg 1990;80 Suppl:1-50.
2. White NJ, Antimalarial drug resistance: the pace quickens. J Antimicrob Chemother 1992;30:571-85.
3. Curtis CF, Impregnated bednets, malaria control and child mortality in Africa. Trop Med Int Health 1996;1:137-8.
4. Greenwood BM, What's new in malaria control? Ann Trop Med Parasitol 1997;91:523-31.
5. Miller LH, Hoffman SL, Research toward vaccines against malaria. Nat Med 1998;(4 Suppl):156-60.
6. Hoffman SL, Malaria vaccine development: a multi-immune response approach. Washington, D.C.: American Society for Microbiology; 1996.
7. Bouharoun-Tayoun H, Oeuvray C, Lunel F, Druilhe P. Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J Exp Med 1995; 182:409-18.
8. Riley EM, Is T-cell priming required for initiation of pathology in malaria infections? Immunol Today 1999;20:228-33.
9. Graves P, Gelband H, Garner P. The SPf66 vaccine: what is the evidence for efficacy. Parasitol Today 1998;4:218-20.
10. Hoffman SL, Crutcher JM, Puri SK, Ansari AA, Villinger F, Franke ED, et al. Sterile protection of monkeys against malaria after administration of interleukin-12. Nat Med 1997;3:80-3.
11. Petersen E, Hogh B, Marbiah NT, David K, Hanson AP. Development of immunity against Plasmodium falciparum: clinical and parasitologic immunity cannot be separated. J Infect Dis 1991;164: 949-53.
12. Snow RW, Omumbo JA, Lowe BS, Molyneux CS, Obiero JO, Palmer A, et al. Relation between severe malaria morbidity in children and level of Plasmodium falciparum transmission in Africa. Lancet 1997;349:1650-4.
13. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. DNA vaccines. Ann Rev Immunol 1997;15:617-48.
14. Wang R, Doolan DL, Le TP, Hedstrom RC, Coonan KM, Charoenvit Y, et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria naked DNA vaccine. Science 1998;282:476-80.
15. Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, Desmons P, et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N Engl J Med 1997;336:86-91.
16. Newbold CI, Craig AG, Kyes S, Berendt AR, Snow RW, Peshu N, et al . PfEMP1, polymorphism and pathogenesis. Ann Trop Med Parasitol 1997;91:551-7.
17. Good MF, Kaslow DC, Miller LH. Pathways and strategies for developing a malaria blood-stage vaccine. Ann Rev Immunol 1998;16:57-87.
18. Bull PC, Lowe BS, Kortok M, Molyneux CS, Newbold CI, Marsh K. Parasite antigens on the infected red cell surface are targets for naturally acquired immunity to malaria. Nat Med 1998;4:358-60.
19. Kaslow DC. Transmission-blocking vaccines: uses and current status of development. Int J Parasitol 1997;27:183-9.
20. Hoffman SL, Rogers WO, Carucci DJ, Venter JC. From genomics to vaccines: malaria as a model system. Nat Med 1998;4:1351-3.
21. Sauerwein RW. Malaria: opnieuw een prioriteit. Mediator 1997;8:9-11.